RenovoRx launches public stock offering
MOUNTAIN VIEW, Calif. - RenovoRx , Inc. (NASDAQ:RNXT), a $35.7 million market cap developer of targeted oncology therapies, has initiated an underwritten public offering of its common stock and ...
Amgen Stock Has Surged. Here’s Where It’s Headed Next.
But this week, the stock jumped again after Amgen issued a strong financial update Tuesday. Its rise helped push up the S&P ...
One year after drug approval, X4 Pharmaceuticals cuts staff
Nearly one year after winning an FDA drug approval to treat an ultra-rare disease, X4 Pharmaceuticals is making layoffs that ...
Jim Cramer on Bristol-Myers Squibb (BMY): “First Schizophrenia Drug in 30 Years”
We recently published a list of Jim Cramer Tells Viewers To Not Trust Billionaires & Discusses These 11 Stocks.
FDA extends target action date for Eton's ET-400
Eton Pharmaceuticals (NASDAQ:ETON) said the FDA has extended the target action date for its market application for ET-400 to May 28 from Feb. 28. The company said it has been notified that the FDA ...
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug ...
Citius Pharma's LYMPHIR gains permanent J-code for billing
Inc. and its subsidiary Citius Oncology, Inc. have announced the assignment of a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for their drug LYMPHIR by the Centers for Medicare & ...
Zacks.com on MSN8h
Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?
Swiss pharma giant Novartis NVS reported better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates. Core earnings (excluding one-time charges) of $1.98 per ...
Lipocine plans phase 3 study for postpartum depression drug
SALT LAKE CITY - Lipocine Inc. (NASDAQ: NASDAQ:LPCN), a biopharmaceutical company with a market capitalization of approximately $24 million, announced today that it will conduct a phase 3 safety and ...
Tonix reports positive results in TNX-1500 phase 1 trial
CHATHAM, N.J. - Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a clinical-stage biotech company with a market capitalization of $28 million, announced today positive outcomes from its Phase 1 ...
BTIG cuts Kura Oncology stock rating to Neutral
BTIG analyst Justin Zelin downgraded Kura Oncology stock (NASDAQ:KURA) from Buy to Neutral. Zelin cited concerns over the recent KOMET-001 study results for the company's drug, ziftomenib. The ...
Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now
We recently compiled a list of the 10 Best Rebound Stocks To Invest In Now. In this article, we are going to take a look at ...